Cargando…

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION

BACKGROUND: There is currently a lack of effective pharmacological treatment for people at Clinical High Risk of Psychosis (CHR), who present with emotional dysregulation and high levels of anxiety. These individuals also show altered neural responses to emotional stimuli in key brain regions implic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Cathy, Wilson, Robin, Appiah-Kusi, Elizabeth, Brammer, Michael, Perez, Jesus, Murray, Robin, Allen, Paul, Bossong, Matthijs, McGuire, Philip, Bhattacharyya, Sagnik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234570/ http://dx.doi.org/10.1093/schbul/sbaa029.705

Ejemplares similares

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2020)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
por: Davies, Cathy, et al.
Publicado: (2021)

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels
por: Bossong, Matthijs G, et al.
Publicado: (2018)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
por: Appiah-Kusi, E., et al.
Publicado: (2020)

T139. OXYTOCIN ENHANCES NEURAL EFFICIENCY IN INFERRING OTHERS’ SOCIAL EMOTIONS IN PEOPLE AT CLINICAL HIGH RISK FOR PSYCHOSIS
por: Schmidt, André, et al.
Publicado: (2020)

T133. NEURAL CORRELATES OF EMOTIONAL PROCESSING IN PSYCHOSIS RISK AND ONSET – A SYSTEMATIC REVIEW AND META-ANALYSIS OF FMRI STUDIES
por: Lukow, Paulina, et al.
Publicado: (2020)

T138. ADOLESCENT ONSET OF PSYCHOSIS IMPACTS SEGREGATION OF CORTICO-SUBCORTICAL NETWORKS DURING DEVELOPMENT
por: Ilzarbe, Daniel, et al.
Publicado: (2020)

T143. RESTING STATE FMRI BASED MULTILAYER NETWORK CONFIGURATION IN PATIENTS WITH SCHIZOPHRENIA
por: Gifford, George, et al.
Publicado: (2020)

T109. TRAVERSING THE TRANSDIAGNOSTIC GAP BETWEEN DEPRESSION, MANIA AND PSYCHOSIS WITH NATURAL LANGUAGE PROCESSING
por: Patel, Rashmi, et al.
Publicado: (2020)

T40. GLYCERYL TRINITRATE IN FIRST EPISODE PSYCHOSIS UNMEDICATED WITH ANTIPSYCHOTICS: A RANDOMISED CONTROLLED FEASIBILITY STUDY
por: Merritt, Kate, et al.
Publicado: (2020)

T97. REAL WORLD IMPLEMENTATION OF A TRANSDIAGNOSTIC RISK CALCULATOR FOR THE AUTOMATIC DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN CLINICAL ROUTINE
por: Oliver, Dominic, et al.
Publicado: (2020)

T127. GENDER DIFFERENCES IN CLINICAL PRESENTATION AND ILLICIT SUBSTANCE USE DURING FIRST EPISODE PSYCHOSIS: AN ELECTRONIC CASE REGISTER NATURAL LANGUAGE PROCESSING ANALYSIS
por: Irving, Jessica, et al.
Publicado: (2020)

T3. EMOTION RECOGNITION AND CHILDHOOD ADVERSITY IN INDIVIDUALS AT CLINICAL HIGH RISK OF PSYCHOSIS
Publicado: (2020)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

T183. LOW LEVELS OF VITAMIN D ARE ASSOCIATED WITH REDUCED CORTICAL THICKNESS AND SURFACE AREA IN FRONTAL, TEMPORAL AND OCCIPITAL REGIONS IN FIRST-EPISODE PSYCHOSIS PATIENTS
por: Ciufolini, Simone, et al.
Publicado: (2020)

T57. IMPAIRED FACIAL EMOTION RECOGNITION IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: CORRELATIONS WITH SCHIZOTYPY AND PARANOID LEVEL
por: Seo, Eunchong, et al.
Publicado: (2020)

T52. COGNITION, METACOGNITION AND SOCIAL COGNITION AFTER A FIRST EPISODE PSYCHOSIS. PRELIMINARY RESULTS FROM A 5-YEAR-FOLLOW-UP STUDY
por: Tripoli, Giada, et al.
Publicado: (2020)

The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
por: Wilson, Robin Paul, et al.
Publicado: (2018)

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

T230. IDENTITY IN THE EARLY STAGES OF PSYCHOSIS: PERSPECTIVES OF CANADIAN EARLY PSYCHOSIS CLINICIANS
por: Ben-David, Shelly, et al.
Publicado: (2020)

T177. CANNABIDIOL AS A POTENTIAL PREVENTATIVE TREATMENT IN A NEUREGULIN-1 MOUSE MODEL OF SCHIZOPHRENIA
por: Visini, Gabriela, et al.
Publicado: (2020)

T85. LIVING WITH PSYCHOSIS IN LATER LIFE
por: Galletly, Cherrie, et al.
Publicado: (2020)

T155. PROGRESSION OF NEUROANATOMICAL ABNORMALITIES AFTER FIRST-EPISODE OF PSYCHOSIS: A 3-YEAR LONGITUDINAL STRUCTURAL MRI STUDY
por: Akudjedu, Theophilus, et al.
Publicado: (2020)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

T237. PERSON-CENTERED PSYCHOSIS CARE –HOW INCREASING PERSON-CENTEREDNESS IN PSYCHOSIS INPATIENT CARE RELATE TO CARE CONSUMPTION AND WARD BURDEN
por: Allerby, Katarina, et al.
Publicado: (2020)

T244. FURTHER EVIDENCE SUPPORTING COORDINATED SPECIALTY CARE FOR EARLY PSYCHOSIS: FINDINGS FROM THE SAMHSA SUPPORTED PENN PSYCHOSIS EVALUATION AND RECOVERY CENTER (PERC)
por: Kohler, Christian, et al.
Publicado: (2020)

T152. AZERI RECENT ONSET ACUTE PHASE PSYCHOSIS SURVEY (ARAS COHORT): PRELIMINARY REPORTS FROM AN OBSERVATIONAL COHORT OF FIRST EPISODE PSYCHOSIS IN IRAN
por: Farhang, Sara, et al.
Publicado: (2020)

T83. SUBSTANCE-INDUCED PSYCHOSIS LINKED TO BOTH INFECTIONS AND SCHIZOPHRENIA
por: Hjorthøj, Carsten, et al.
Publicado: (2020)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2019)

S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE
por: Colizzi, Marco, et al.
Publicado: (2018)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

T115. PERSONALITY ACROSS THE PSYCHOSIS CONTINUUM: A FINE-GRAINED PERSPECTIVE
por: Begemann, Marieke, et al.
Publicado: (2020)

T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL
por: Schlögelhofer, Monika, et al.
Publicado: (2020)

T48. DEVIATIONS IN MICRO AND MACRO WHITE MATTER STRUCTURES IN PSYCHOSIS PRONENESS
por: Arslan, Seda, et al.
Publicado: (2020)

T238. RATES AND PREDICTORS OF RELAPSE IN AN AUSTRALIAN FIRST EPISODE PSYCHOSIS COHORT
por: Brown, Ellie, et al.
Publicado: (2020)

T66. IS COGNITIVE PERFORMANCE ASSOCIATED WITH ANXIETY AND DEPRESSION IN FIRST-EPISODE PSYCHOSIS?
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34b7ftqmc66o4ov3q3i3bkk9r1